Promising patient studies surrounding the medication Retatrutide , specifically the 120mg formulation referred to as ZPHC, reveal a considerable effect on body mass loss and linked chronic illnesses . Scientists posit that this combined agonist , influencing both GLP-1 and GIP pathways , has the potential to represent a major improvement in the ma